Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001333141 XXXXXXXX LIVE 006 Common Stock, par value $0.0001 per share 01/01/2026 false 0001818382 020751103 HUMACYTE, INC. 2525 East North Carolina Highway 54 Durham NC 27713 Robert A. Grauman 646 202-2932 145 West 86 Street New York NY 10024 Thomas D. Brouillard 781 699 9000 Fresenius Medical Care Holdings, Inc. 920 Winter Street Waltham MA 02451-1547 Christof Koester 011 49 6172 609 0 Fresenius Medical Care AG Else-Kroner Strasse 1 Bad Homburg 2M 61352 0000042872 N Fresenius Medical Care Holdings, Inc. WC N NY 0.00 18312735.00 0.00 18312735.00 18312735.00 N 9.5 CO 0001333141 N Fresenius Medical Care AG AF N 2M 0.00 18312735.00 0.00 18312735.00 18312735.00 N 9.5 CO Common Stock, par value $0.0001 per share HUMACYTE, INC. 2525 East North Carolina Highway 54 Durham NC 27713 This Amendment No. 6 amends certain information contained in the Schedule 13D originally filed by Fresenius Medical Care Holdings, Inc., a New York Corporation ("FMCH") and Fresenius Medical Care AG a German stock corporation ("FME AG") on September 2, 2021, as previously amended by Amendment No. 1 filed December 1, 2023, Amendment No. 2 filed March 7, 2024, Amendment No 3 filed November 18, 2024, Amendment No 4 filed May 22, 2025 and Amendment No 5 filed solely by FME AG on October 16 2025 (as so amended, the "Schedule 13D"), with respect to the common stock, par value $0.0001 per share (the "Common Stock") of Humacyte, Inc., a Delaware corporation, formerly known as Alpha Healthcare Acquisition Corp. (the "Issuer" or "Humacyte"). Capitalized terms not otherwise defined herein have the meanings set forth in the Schedule 13D. Except as provided herein, this Amendment No. 6 does not modify any of the information previously reported on the Schedule 13D. Effective January 1, 2026, Charles Hugh-Jones, M.D. FACP assumed office as a member of the Management Board and Chief Medical Officer of FME AG, and as a member of the Board of Directors of FMCH. Dr. Hugh-Jones succeeds Franklin Maddux M.D., who retired from his positions with FME AG and its affiliates effective December 31, 2025. In addition, also effective January 1, 2026, Mr. Joseph E. Turk assumed office as a member of the Management Board and Chief Executive Officer of FME AG's global operating segment Care Enablement. Mr. Turk succeeds Dr. Katarzyna Mazur-HofsaeSS, who retired from her positions with FME AG and its affiliates effective December 31, 2025. Schedule I to this Schedule 13D in the form annexed to this Schedule 13D (Amendment No 2), as previously amended, is hereby further amended (i) by deleting each of Dr. Maddux and Dr. Mazur-HofsaeSS from the list of members of the FME AG Management Board set forth therein and replacing them on such list with Dr. Hugh-Jones and Mr. Turk, and (ii) by deleting Dr. Maddux from the list of members of the Board of Directors of FMCH set forth therein and replacing him on such list with Mr. Turk. The business address of each of Dr Hugh-Jones and Mr. Turk is c/o FME AG, at its address set forth in this Schedule 13D. The present principal occupation or employment of Dr Hugh-Jones and Mr. Turk is their respective positions with FME AG set forth in Item 2(a) of this Schedule 13D (Amendment No. 6). During the last five years, to the knowledge of the Filing Persons, neither Dr. Hugh-Jones nor Mr. Turk has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), nor was either of them a party to a civil proceeding of a United States judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Dr. Hugh-Jones is a citizen of the U.K. Mr. Turk is a citizen of the United States. On the date of this Schedule 13D (Amendment No. 6), FMCH is the beneficial owner of 18,312,735 shares of the Issuer's Common Stock, constituting approximately 9.5% of the Issuer's outstanding voting shares. Such percentage ownership is calculated by reference to 192,996,511 shares outstanding as of December 15, 2025, comprising 187,727,321 shares outstanding as shown on the cover page of the Issuer's Form 10-Q filed November 12, 2025 plus 5,725,190 shares issued on December 15, as reported in the Issuer's Form 8-K filed that date. All such 18,312,735 Shares are issued and outstanding and owned directly by FMCH. Such 18,312,735 shares of Common Stock exclude any additional contingent shares of Common Stock that may be issued pursuant to the terms of the Business Combination Agreement described in the initial Schedule 13D, and FME AG and FMCH disclaim any present beneficial ownership of any such additional shares. As the record owner of the 18,312,735 shares of Common Stock reported in this Schedule 13D (Amendment No 6), FMCH possesses voting and dispositive power over such shares. FME AG is the indirect sole shareholder of FMCH and may be deemed to be a beneficial owner of such shares. The decrease in the percentage beneficial ownership reported herein from 9.9%, as reported in Schedule 13D (Amendment No. 5) to 9.5%, as reported herein, results solely from an increase in the number of outstanding shares of the Issuer's Common Stock subsequent to the filing of Amendment No. 5 to this Schedule 13D. Neither FME AG nor FMCH has disposed of or acquired any shares of the Issuer's Common Stock subsequent to the filing of their initial Schedule 13D in September 2021. Fresenius Medical Care Holdings, Inc. /s/ Bryan Mello Bryan Mello, Assistant Treasurer 01/09/2026 Fresenius Medical Care AG /s/ Dr. Joerg Haering Dr. Joerg Haering, Member of the Management Board 01/09/2026 /s/ ppa Dr. Angela Koelbl Dr. Angela Koelbl, Registered Manager (Prokurist) 01/09/2026